Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
32.65
+1.67 (5.39%)
At close: Nov 22, 2024, 4:00 PM
32.98
+0.33 (1.01%)
After-hours: Nov 22, 2024, 6:46 PM EST

Company Description

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.

The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.

In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment.

The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research.

The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health, Inc.
Guardant Health logo
Country United States
Founded 2011
IPO Date Oct 4, 2018
Industry Diagnostics & Research
Sector Healthcare
Employees 1,779
CEO Dr. Helmy Eltoukhy Ph.D.

Contact Details

Address:
3100 Hanover Street
Palo Alto, California 94304
United States
Phone 855 698 8887
Website guardanthealth.com

Stock Details

Ticker Symbol GH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001576280
CUSIP Number 40131M109
ISIN Number US40131M1099
Employer ID 45-4139254
SIC Code 8071

Key Executives

Name Position
Dr. AmirAli Talasaz Ph.D. Co-Chief Executive Officer and Director
Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-Chief Executive Officer and Chairman
Michael Bell Chief Financial Officer
Darya Chudova Chief Technology Officer
Dr. Craig Eagle M.D. Chief Medical Officer
Christopher Freeman Chief Commercial Officer
Kumud Kalia Chief Information Officer
Zarak Khurshid Vice President of Investor Relations
Jennifer Higgins Senior Vice President of Public Affairs
Stephen Murphy Senior Vice President of Marketing

Latest SEC Filings

Date Type Title
Nov 18, 2024 144 Filing
Nov 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 144 Filing
Nov 12, 2024 144 Filing
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Oct 24, 2024 8-K Current Report
Oct 7, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals